Literature DB >> 33425743

Analysis of Prognostic Factors of World Health Organization Grade Ⅲ Meningiomas.

Weidong Tian1,2, Jingdian Liu1, Kai Zhao1, Junwen Wang1, Wei Jiang1, Kai Shu1, Ting Lei1.   

Abstract

OBJECTIVE: WHO grade III meningiomas are highly aggressive and lethal. However, there is a paucity of clinical information because of a low incidence rate, and little is known for prognostic factors. The aim of this work is to analyze clinical characteristics and prognosis in patients diagnosed as WHO grade III meningiomas.
METHODS: 36 patients with WHO grade III meningiomas were enrolled in this study. Data on gender, age, clinical presentation, preoperative Karnofsky Performance Status (KPS), histopathologic features, tumor size, location, radiologic findings, postoperative radiotherapy (RT), surgical treatment, and prognosis were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method. Univariate and multivariate analysis were conducted by the Cox regression model.
RESULTS: Median PFS is 20 months and median OS is 36 months in 36 patients with WHO grade III meningiomas. Patients with secondary tumors which transformed from low grade meningomas had lower PFS (p=0.0014) compared with primary group. Multivariate analysis revealed that tumors location (PFS, p=0.016; OS, p=0.013), Ki-67 index (PFS, p=0.004; OS, p<0.001) and postoperative radiotherapy (PFS, p=0.006; OS, p<0.001) were associated with prognosis.
CONCLUSION: WHO grade III meningiomas which progressed from low grade meningiomas were more prone to have recurrences or progression. Tumors location and Ki-67 index can be employed to predict patient outcomes. Adjuvant radiotherapy after surgery can significantly improve patient prognosis.
Copyright © 2020 Tian, Liu, Zhao, Wang, Jiang, Shu and Lei.

Entities:  

Keywords:  WHO; malignancy; meningioma; prognosis; recurrence

Year:  2020        PMID: 33425743      PMCID: PMC7793968          DOI: 10.3389/fonc.2020.593073

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  29 in total

1.  Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012.

Authors:  Andrew Orton; Jonathan Frandsen; Randy Jensen; Dennis C Shrieve; Gita Suneja
Journal:  J Neurosurg       Date:  2017-07-21       Impact factor: 5.115

Review 2.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

3.  Management trends for anaplastic meningioma with adjuvant radiotherapy and predictors of long-term survival.

Authors:  Ahmad Alhourani; Zaid Aljuboori; Mehran Yusuf; Shiao Y Woo; Eyas M Hattab; Norberto Andaluz; Brian J Williams
Journal:  Neurosurg Focus       Date:  2019-06-01       Impact factor: 4.047

4.  Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy.

Authors:  Sebastian Adeberg; Christian Hartmann; Thomas Welzel; Stefan Rieken; Daniel Habermehl; Andreas von Deimling; Jürgen Debus; Stephanie E Combs
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

5.  Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.

Authors:  Suresh K Balasubramanian; Mayur Sharma; Danilo Silva; Vidhya Karivedu; Philipp Schmitt; Glen H Stevens; Gene H Barnett; Richard A Prayson; Paul Elson; John H Suh; Erin S Murphy; Samuel T Chao
Journal:  J Neurooncol       Date:  2016-11-18       Impact factor: 4.130

6.  The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection.

Authors:  Douglas A Hardesty; Andrew B Wolf; David G Brachman; Heyoung L McBride; Emad Youssef; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai
Journal:  J Neurosurg       Date:  2013-02-08       Impact factor: 5.115

7.  High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.

Authors:  Stéphane Goutagny; Jean C Nault; Maxime Mallet; Dominique Henin; Jessica Z Rossi; Michel Kalamarides
Journal:  Brain Pathol       Date:  2013-12-23       Impact factor: 6.508

8.  Prognostic factors and the management of anaplastic meningioma.

Authors:  Gui-Jun Zhang; Yun-Sheng Zhang; Guo-Bin Zhang; Da Li; Li-Wei Zhang; Zhen Wu; Jun-Ting Zhang
Journal:  Clin Neurol Neurosurg       Date:  2018-03-27       Impact factor: 1.876

9.  Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas--an immunohistochemical study.

Authors:  Andreas H Habberstad; Sasha Gulati; Sverre H Torp
Journal:  Diagn Pathol       Date:  2011-05-24       Impact factor: 2.644

10.  Tumor-associated macrophage infiltration in meningioma.

Authors:  Dustin T Proctor; Jordan Huang; Sanju Lama; Abdulrahman Albakr; Guido Van Marle; Garnette R Sutherland
Journal:  Neurooncol Adv       Date:  2019-09-19
View more
  2 in total

1.  A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma.

Authors:  Peng Gao; Tengxiao Kong; Xuqiang Zhu; Yingwei Zhen; Hongjiang Li; Di Chen; Shanpeng Yuan; Dongtao Zhang; Henan Jiao; Xueyuan Li; Dongming Yan
Journal:  Front Oncol       Date:  2021-10-11       Impact factor: 6.244

2.  Inflammatory Tumor Microenvironment in Cranial Meningiomas: Clinical Implications and Intraindividual Reproducibility.

Authors:  Johannes Wach; Tim Lampmann; Ági Güresir; Hartmut Vatter; Ulrich Herrlinger; Albert Becker; Marieta Toma; Michael Hölzel; Erdem Güresir
Journal:  Diagnostics (Basel)       Date:  2022-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.